Barr Challenges Savient’s Oxandrin Patents

Law360, New York (September 27, 2006, 12:00 AM EDT) -- Generic drug maker Barr Laboratories Inc. is going after Savient Pharmaceuticals Inc.’s patents covering its lucrative Oxandrin tablets that promote weight gain.

Barr Laboratories, a subsidiary of Barr Pharmaceuticals Inc., confirmed Tuesday that it is challenging Savient’s patents through its June filing of an abbreviated drug application (ANDA) with the U.S. Food and Drug Administration for the product.

Earlier on Tuesday, Savient lodged a patent infringement lawsuit in the U.S. District Court for the District of New Jersey to block Barr from taking steps toward the...
To view the full article, register now.